Literature DB >> 9011482

Duration of HCV infection as a predictor of nonresponse to interferon.

A Craxì1, V Di Marco, C Cammà, P Almasio, S Magrin.   

Abstract

Duration of hepatitis C virus (HCV) infection is a key feature in determining responsiveness to interferon (IFN). Studies assessing its value as a predictive factor in chronic HCV infection show that a long duration of infection reduces the likelihood of a sustained response to IFN (defined as ALT normalization and clearance of serum HCV-RNA). The effect of HCV infection duration is independent of the presence of cirrhosis and level of HCV viremia. Meta-analysis of IFN trials in acute HCV infection shows an obvious effect of the drug on long-term ALT normalization and HCV-RNA clearance. Treatment of HCV infection during the acute or early chronic phase could therefore maximize therapeutic effectiveness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9011482     DOI: 10.1007/bf02087881

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  60 in total

1.  The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha.

Authors:  D Palmović; I Kurelac; J Crnjaković-Palmović
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

2.  Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.

Authors:  L Pagliaro; A Craxí; C Cammaá; F Tiné; V Di Marco; O Lo Iacono; P Almasio
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

3.  Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis.

Authors:  N Enomoto; M Kurosaki; Y Tanaka; F Marumo; C Sato
Journal:  J Gen Virol       Date:  1994-06       Impact factor: 3.891

4.  Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.

Authors:  E Orito; M Mizokami; T Nakano; H Terashima; O Nojiri; K Sakakibara; M Mizuno; M Ogino; M Nakamura; Y Matsumoto
Journal:  J Med Virol       Date:  1994-12       Impact factor: 2.327

5.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

6.  Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C.

Authors:  R Pérez; R Pravia; A Linares; M Rodríguez; J L Lombraña; A Suárez; S Riestra; C A Navascués; L Rodrigo
Journal:  Gut       Date:  1993       Impact factor: 23.059

7.  Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.

Authors:  T Aiyama; K Yoshioka; H Hirofuji; A Kusakabe; M Yamada; K Tanaka; S Kakumu
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

8.  Response to interferon alpha therapy is influenced by the iron content of the liver.

Authors:  D H Van Thiel; L Friedlander; S Fagiuoli; H I Wright; W Irish; J S Gavaler
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

9.  Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.

Authors:  T Suzuki; E Tanaka; A Matsumoto; A Urushihara; T Sodeyama
Journal:  J Med Virol       Date:  1995-06       Impact factor: 2.327

10.  Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response.

Authors:  G Mazzella; A Salzetta; S Casanova; M C Morelli; N Villanova; R Miniero; S Sottili; V Novelli; A Cipolla; D Festi
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

View more
  2 in total

1.  Virus genotype 1b and long-term response to interferon alpha monotherapy in children with chronic hepatitis C.

Authors:  Iwona Mozer-Lisewska; Wojciech Słuzewski; Khaled Ali Youseif; Magdalena Figlerowicz; Arleta Kowala-Piaskowska
Journal:  Eur J Pediatr       Date:  2003-08-22       Impact factor: 3.183

2.  Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response.

Authors:  Richard Sallie
Journal:  Virol J       Date:  2007-03-13       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.